Welcome to HitGen

HitGen Inc.

HitGen has established a drug discovery research platform for small molecules and nucleic acid drugs centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies.

Read More

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.


For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.

For media inquiries: media@hitgen.com

For investor inquiries: investors@hitgen.com  

For business development: bd@hitgen.com  


Read More

History and Honor

  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012

Publications

Read More

Download Center

  • DEL for
    DNA encoded library (DEL) selection has been applied on various target classes and different modalities, yielding ligands progressed into different stages of drug development. In this session, we review the major advantages and potential challenges of DEL selection on diverse targets including PPI, kinases, GPCRs, RNAs and etc., as well as different modalities like covalent ligands and Protein degraders.
    Download
  • OpenDEL®
    OpenDEL® has previously been released by HitGen as a self-serve product in 2015 (https://www.nature.com/articles/d43747-020-00040-4). After several years of evolution, it now contains small molecule DELs with high diversity and drug-like space and helps to increase the possibility of finding potential hits in an efficient and cost-effective manner.
    Download
  • Novel BRD4 Degrader Discovery using DEL Technology
    DEL selection is an affinity-based approach to recognize compounds interacting with the target, including the compounds modulating target function(s) or simply binding to the protein. The architecture of a DNA Encoded Compound is very similar to proteolysis targeting chimeras (PROTAC) as shown in the following figure. Both DEL compound and PROTAC molecule require covalent linkage of two molecules with known attachment points that have minimal impact to the binding.
    Download
Read More

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
验证码
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information